DBV Technologies secures €166.7M from full exercise of warrants after positive VITESSE trial

DBV Technologies S.A.

€166.7M gross proceeds from full exercise of ABSA Warrants (34.1M) and BS Warrants (71.0M) issued March 2025.
Proceeds to fund BLA submission and U.S. launch preparations for VIASKIN Peanut patch in children 4-7 years if approved.
Company expects to be funded for at least 12 months, including through potential commercial launch.
Exercise triggered by positive VITESSE Phase 3 topline results announced December 16, 2025; no warrants remain outstanding.
59.7M new ordinary shares issued; additional pre-funded warrants may access up to 154M new shares in future.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.